NCT06453915RecruitingEarly phase 1
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD. The goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 24 May 2024
- Start date
- 30 Apr 2025
- Primary completion date
- Jul 2027
- Lead sponsor
- University of California, Davis
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06453915
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 12
- From 30 Apr 2025 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET/CT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available)
- Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.
- Currently on anticoagulant therapy
- Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans
Other illness
- History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.
- Pre-existing neurodegenerative disorders and dementia
- Significant history of major skull concussion or repetitive head trauma
Other
- Uncontrolled claustrophobia
- Body weight \>225 kg due to limitations of the scanner bed
- Prisoners
- Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.
Who the study is looking for
- Participants \>=18 years age
- Participants who have or have planned a liver biopsy as:
- standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or
- as part of another Clinical Trials study for MASH, or
- standard of care prior to undergoing bariatric surgery
- Liver biopsy needs to be within 6 months of planned study-related imaging
- Ability to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UC Davis EXPLORER Molecular Imaging Center Coordinator of this site? Confirm its status | Sacramento | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.